K251634

Substantially Equivalent

LZI Fentanyl III Enzyme Immunoassay

Applicant: Lin-Zhi International, Inc.
Product code: DJG
Advisory panel: Clinical Toxicology
Date received: 2025-05-29
Decision date: 2025-06-18
Decision: Substantially Equivalent
Clearance type: Special
Location: Santa Clara, CA, US

Download summary PDF View on FDA.gov ↗

Data sourced from openFDA. This site is unofficial and independent of the FDA.